Shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) fell 2.3% during trading on Wednesday after an insider sold shares in the company. The company traded as low as $19.49 and last traded at $19.77, with a volume of 62,204 shares trading hands. The stock had previously closed at $20.23.

Specifically, COO Gad Soffer sold 5,356 shares of the company’s stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $22.41, for a total value of $120,027.96. Following the completion of the sale, the chief operating officer now owns 146,460 shares of the company’s stock, valued at approximately $3,282,168.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Christopher Haqq sold 1,346 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $22.32, for a total transaction of $30,042.72. Following the completion of the sale, the insider now directly owns 295,294 shares of the company’s stock, valued at approximately $6,590,962.08. The disclosure for this sale can be found here. 16.10% of the stock is currently owned by insiders.

Several brokerages have recently weighed in on ATRA. JMP Securities reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research report on Saturday, July 9th. Zacks Investment Research raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 2nd. Canaccord Genuity reissued a “buy” rating on shares of Atara Biotherapeutics in a research report on Tuesday, June 7th. Jefferies Group reissued a “buy” rating and set a $25.00 target price on shares of Atara Biotherapeutics in a research report on Tuesday, August 9th. Finally, Goldman Sachs Group Inc. cut shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and decreased their target price for the company from $23.00 to $16.00 in a research report on Thursday, September 15th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Atara Biotherapeutics presently has a consensus rating of “Hold” and a consensus target price of $26.14.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/atara-biotherapeutics-inc-atra-trading-down-2-3-after-insider-selling.html

The stock has a 50-day moving average price of $21.37 and a 200-day moving average price of $20.02. The company’s market capitalization is $573.92 million.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.05. Equities analysts expect that Atara Biotherapeutics Inc. will post ($2.85) EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of ATRA. FMR LLC boosted its position in Atara Biotherapeutics by 29.9% in the second quarter. FMR LLC now owns 3,125,407 shares of the company’s stock valued at $70,353,000 after buying an additional 720,313 shares during the period. Redmile Group LLC boosted its position in Atara Biotherapeutics by 5.9% in the second quarter. Redmile Group LLC now owns 2,408,970 shares of the company’s stock valued at $54,226,000 after buying an additional 133,205 shares during the period. BlackRock Fund Advisors boosted its position in Atara Biotherapeutics by 18.6% in the second quarter. BlackRock Fund Advisors now owns 913,922 shares of the company’s stock valued at $20,572,000 after buying an additional 143,242 shares during the period. Bridger Management LLC purchased a new position in Atara Biotherapeutics during the first quarter valued at approximately $14,072,000. Finally, Vanguard Group Inc. boosted its position in Atara Biotherapeutics by 20.3% in the second quarter. Vanguard Group Inc. now owns 679,690 shares of the company’s stock valued at $15,300,000 after buying an additional 114,734 shares during the period. Institutional investors own 75.50% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.